EICHORCondition: Moderate-to-Severe Atopic Dermatitis · Sponsor: Nektar Therapeutics
This is an interventional, randomized, parallel group, treatment, Phase 3, double blind study to assess the effect of Rezpegaldesleukin in participants 12 years of age or older with moderate to severe atopic dermatitis, as compared to placebo. The estimated participant overall duration is approximately 15 months.
This description comes directly from the study's public registry record.
Nektar Recruitment · 855-482-8676 · StudyInquiry@nektar.com
Always discuss trial participation with your own doctor first.
| Nektar Investigative Site | Fountain Valley, California, United States | Recruiting |
| Nektar Investigative Site | Los Angeles, California, United States | Recruiting |
| Nektar Investigative Site | Boca Raton, Florida, United States | Recruiting |
| Nektar Investigative Site | St. Petersburg, Florida, United States | Recruiting |
| Nektar Investigative Site | Macon, Georgia, United States | Recruiting |
| Nektar Investigative Site | Normal, Illinois, United States | Recruiting |
| Nektar Investigative Site | Bowling Green, Kentucky, United States | Recruiting |
| Nektar Investigative Site | Owensboro, Kentucky, United States | Recruiting |
| Nektar Investigative Site | Lafayette, Louisiana, United States | Recruiting |
| Nektar Investigative Site | Omaha, Nebraska, United States | Recruiting |
| Nektar Investigative Site | Clifton, New Jersey, United States | Recruiting |
| Nektar Investigative Site | New York, New York, United States | Recruiting |
Sponsor or site team? See the site landscape for this trial — listed sites, countries, and recruiting-density context.
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07690371